GL1X · GenesisL1 explorer

MolNFT v1 · #228779 · protein

Q93074: AlphaFold monomer V2.0 prediction for mediator of RNA polymerase II transcription subunit 12 (Q93074)

Q93074: “AlphaFold monomer V2.0 prediction for mediator of RNA polymerase II transcription subunit 12 (Q93074)”. 20 pockets (best druggability 0.83). MolNFT v1 #228779 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

3D structure of Q93074: AlphaFold monomer V2.0 prediction for mediator of RNA polymerase II transcription subunit 12 (Q93074) (MolNFT v1 / AlphaFold)
3D structure of Q93074: AlphaFold monomer V2.0 prediction for mediator of RNA polymerase II transcription subunit 12 (Q93074) (MolNFT v1 / AlphaFold)
Accession
Q93074
Type
protein
Length
2,177 residues
Chains
1
Deposited
01-JUL-21
Collection
MolNFT v1 / AlphaFold
Contract
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
Owner
0x5e58272ea25a05e06901A2eAe9f63939b344e0c6
Molecule
Mediator of RNA polymerase II transcription subunit 12
UniProt
Q93074
Pockets
20 · best druggability 0.83

Structure

1 distinct chain · 46% helix, 1% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMediator of RNA polymerase II transcription subunit 12protein217746% helix, 1% strandQ93074

Pockets

20 pockets found on a 1 Å grid, 13 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110820.830.8481empty
29990.740.7782empty
37160.730.7967empty
43900.660.7940empty
52600.640.8227empty

Compared structures

  • 8TQC · Structure of the human CDK8 kinase module · an experimental structure of the same protein · chain A against C, TM-score 0.54
  • 8TQW · Structure of human transcriptional Mediator complex · an experimental structure of the same protein · chain A against c, TM-score 0.54
  • 8TQ2 · Structure of the kinase lobe of human CDK8 kinase module · an experimental structure of the same protein · chain A against C, TM-score 0.03

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.